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OBJECTIVES This study was designed to investigate whether nicotinamide adenine dinucleotide
3-phosphate (reduced form) (NADPH) oxidase is expressed in the human heart and whether
it contributes to reactive oxygen species (ROS) production in heart failure.
BACKGROUND A phagocyte-type NADPH oxidase complex is a major source of ROS in the vasculature and
is implicated in the pathophysiology of hypertension and atherosclerosis. An increase in
myocardial oxidative stress due to excessive production of ROS may be involved in the
pathophysiology of congestive heart failure. Recent studies have suggested an important role
for myocardial NADPH oxidase in experimental models of cardiac disease. However, it is
unknown whether NADPH oxidase is expressed in the human myocardium or if it has any
role in human heart failure.
METHODS Myocardium of explanted nonfailing (n  9) and end-stage failing (n  13) hearts was
studied for the expression of NADPH oxidase subunits and oxidase activity.
RESULTS The NADPH oxidase subunits p22phox, gp91phox, p67phox, and p47phox were all expressed at
messenger ribonucleic acid and protein level in cardiomyocytes of both nonfailing and failing
hearts. NADPH oxidase activity was significantly increased in end-stage failing versus
nonfailing myocardium (5.86  0.41 vs. 3.72  0.39 arbitrary units; p  0.01). The overall
level of oxidase subunit expression was unaltered in failing compared with nonfailing hearts.
However, there was increased translocation of the regulatory subunit, p47phox, to myocyte
membranes in failing myocardium.
CONCLUSIONS This is the first report of the presence of NADPH oxidase in human myocardium. The
increase in NADPH oxidase activity in the failing heart may be important in the
pathophysiology of cardiac dysfunction by contributing to increased oxidative stress. (J Am
Coll Cardiol 2003;41:2164–71) © 2003 by the American College of Cardiology Foundation
Considerable evidence supports a role for oxidative stress
due to excessive production of reactive oxygen species
(ROS) such as superoxide (O2
) in the pathophysiology of
congestive heart failure (CHF). Increased oxidative stress
may contribute to contractile dysfunction, endothelial dys-
function, myocyte apoptosis and necrosis, remodeling of the
extracellular matrix, and the progressive downward spiral of
heart failure (1,2). Patients with CHF have elevated plasma
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levels of thiobarbituric acid-reactive substances (3) and
pericardial levels of 8-isoprostaglandin F2-alpha (4), and
these markers of increased oxidative stress correlate with
functional severity of CHF (4). Aspects of the CHF
phenotype, such as the impairment of nitric oxide-
dependent vasodilation, can be restored to normal by acute
treatment with antioxidants (5).
Experimental studies also support a role for increased
oxidative stress in failing myocardium (1,6). In isolated
cardiac myocytes, a moderate increase in ROS induces a
phenotype characterized by hypertrophy and apoptosis (7).
In experimental pressure-overload cardiac hypertrophy, the
transition to heart failure is associated with increased
oxidative stress and can be suppressed by treatment with the
antioxidant vitamin E (8). Likewise, progressive myocardial
remodeling following experimental myocardial infarction
could be inhibited by antioxidant treatment (9).
Because these studies suggest an important role for
oxidative stress in ventricular remodeling and the progres-
sion to CHF, it is important to define the nature and
sources of ROS production in the failing heart. Recent
animal studies have suggested that both mitochondria and
xanthine oxidase may be significant contributors to ROS
production in experimental heart failure (6,10,11). How-
ever, there is still a paucity of data regarding potential ROS
sources in the failing human myocardium (12).
In the vasculature, accumulating evidence from experi-
mental and clinical studies indicates that a phagocyte-type
nicotinamide adenine dinucleotide 3-phosphate (reduced
form) (NADPH) oxidase complex is a major source of ROS
in several disease settings (13). This enzymatic complex was
initially discovered in neutrophils, where it is activated
during phagocytosis, resulting in high-output ROS (O2
)
production, and plays an essential role in nonspecific host
defense against infective microbes (14). A similar or iden-
tical enzyme complex is also expressed in many non-
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phagocytic cells. Reactive oxygen species production by the
NADPH oxidase in smooth muscle and endothelial cells of
the vessel wall has been implicated in the genesis of hyperten-
sive vascular smooth muscle hypertrophy (13,15,16), athero-
sclerosis (17), and endothelial dysfunction (18). Impor-
tantly, NADPH oxidase is known to be activated by several
stimuli of relevance to cardiovascular pathophysiology, in-
cluding angiotensin II, noradrenaline, tumor necrosis
factor-alpha (TNF-alpha), and increased mechanical forces
(13,14).
Recent experimental studies suggest a role for NADPH
oxidase in cardiac pathophysiology. We have reported an
increased myocardial expression and activity of NADPH
oxidase in experimental pressure-overload cardiac hypertro-
phy (19) and suggested a role for ROS derived from this
oxidase in the genesis of cardiac contractile dysfunction in
this setting (20). The development of experimental angio-
tensin II-induced cardiac hypertrophy was found to be
inhibited in mice lacking a functional NADPH oxidase
(21). Likewise, ROS production by NADPH oxidase was
implicated in alpha-adrenergic agonist-induced cardiomyo-
cyte hypertrophy (22).
The aims of the present study were to investigate whether
NADPH oxidase is expressed in the human heart, and if so,
whether its expression or activity are altered in the failing
heart.
METHODS
Patients. All studies conformed to the Declaration of
Helsinki and institutional ethical regulations. Explanted
failing hearts were obtained from patients undergoing car-
diac transplantation for end-stage CHF secondary to idio-
pathic dilated cardiomyopathy (n  13; mean age 53  3.2
years). All patients had New York Heart Association class
IV CHF, with a mean pretransplant left ventricular ejection
fraction of 22%  4%. None had been treated with left
ventricular assist devices or had received chronic intravenous
inotropic support over at least seven days immediately
before transplantation. Heart failure therapy consisted of
angiotensin-converting enzyme inhibitors and diuretics in
all patients. Nonfailing hearts (n  9; mean age 47  4.4
years) were obtained from prospective multiorgan donors
who had died from head trauma or intracranial bleeds; these
hearts were unsuitable for transplantation for technical
reasons. All tissues were stored at 80°C until further
analyses.
Myocardial NADPH oxidase activity. Specific left ven-
tricular myocardial NADPH oxidase activity was measured
in total tissue homogenates of explanted failing and non-
failing hearts by lucigenin-enhanced chemiluminescence
(23,24). Experiments were performed on a microplate
luminometer (Anthos “Lucy 1,” Labtech; 37°C) using 100
g protein/well, NADPH 300 mol/l, and a non-redox
cycling dose of lucigenin (5 mol/l). Oxidase activity was
also measured in the presence of a cell-permeable O2

scavenger 4,5-dihydroxy-1,3-benzene-disulfonic acid (Ti-
ron, 20 mmol/l) to confirm that the measured signal was
attributable to superoxide. Experiments were also per-
formed with the following pharmacologic inhibitors to
confirm that the measured activity was attributable to
NADPH oxidase: a flavoprotein inhibitor, diphenylene-
iodonium (DPI, 10 mol/l); a nitric oxide synthase inhi-
bitor, N-nitro-L-arginine methyl ester hydrochloride
(L-NAME, 100 mol/l); a mitochondrial site I electron
transport inhibitor, rotenone (20 mol/l); or a xanthine
oxidase inhibitor, oxypurinol (100 mol/l) (22). A buffer
blank (2% of the homogenate signal) was subtracted from
each reading. Chemiluminescence readings were expressed
as integrated light units over 40 min, a period over which
maximal chemiluminescence was achieved; this method of
quantifying activity (area under the curve) correlates well
with enzyme rates measured by other methods such as O2
consumption or cytochrome c reduction (23).
Immunoblotting. Left ventricular tissue homogenate was
immunoblotted for the NADPH oxidase subunits p22phox,
gp91phox, p67phox, and p47phox, as well as the myofilament
protein cardiac troponin I, which was used as a loading
control. Monoclonal anti-p22phox and anti-troponin I anti-
bodies were kind gifts from Dr. A. Verhoeven (Amsterdam,
Netherlands) and Dr. P. Cummins (Birmingham, United
Kingdom), respectively. The polyclonal anti-gp91phox anti-
body was kindly provided by Dr. M. Quinn (Montana).
Anti-p67phox and anti-p47phox polyclonals were purchased
from Transduction Laboratories (Oxford, United King-
dom). Anti-mouse or -rabbit horseradish peroxidase-
conjugated secondary antibodies were used. Immunoreac-
tive bands were visualized by enhanced chemiluminescence
and quantified by densitometry. Results are expressed rela-
tive to cardiac troponin I abundance.
Immunohistochemistry. Cryostat sections (7 m thick)
were postfixed in acetone/methanol (1:1) at 20°C. Non-
specific binding was prevented by preincubation in
phosphate-buffered saline containing 5% BSA for 30 min at
room temperature. The antibodies used were polyclonal
anti-p47phox and anti-gp91phox antibodies (as described
earlier), and monoclonal anti-vinculin and anti-alpha-
actinin antibodies (Sigma, Poole, United Kingdom). Anti-
bodies were applied to sections for 1 h at 25°C. FITC-
conjugated sheep anti-rabbit immunoglobulin G or Texas
Red-conjugated anti-mouse immunoglobulin G were the
Abbreviations and Acronyms
CHF  congestive heart failure
DPI  diphenyleneiodonium
L-NAME  N-nitro-L-arginine methyl ester
hydrochloride
mRNA  messenger ribonucleic acid
NADPH  nicotinamide adenine dinucleotide
3-phosphate (reduced form)
O2
  superoxide
ROS  reactive oxygen species
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secondary antibodies. Sections were washed and mounted in
aqueous medium Vectashield (Vector) containing DAPI.
Fluorescence was observed either with a DMRB Leica
microscope equipped with epifluorescence optics or a Nikon
E600FN upright microscope equipped with a Bio-Rad
MRC-1024/2-P multiphoton imaging attachment.
Reverse transcription-polymerase chain reaction. Total
RNA was extracted with Trizol Reagent (Roche). Moloney
murine leukemia virus reverse transcriptase (200 U, Pro-
mega) was used for reverse transcription. C-deoxyribonucleic
acid was amplified using 2.5 U Taq deoxyribonucleic acid
polymerase (Roche) and 0.5 mol/l of specific sense and
antisense primers for gp91phox, p22phox, p47phox, p67phox, or
cardiac troponin I (Table 1). The linear phase of amplifi-
cation was determined for each primer set to allow semi-
quantitative PCR analysis. All samples were run in dupli-
cate. Gels were quantified by densitometry, and NADPH
oxidase subunit expression level was normalized by cardiac
troponin I. In preliminary experiments, we confirmed that
myocardial messenger ribonucleic acid (mRNA) expression
of troponin I did not vary significantly between normal and
failing human myocardium (data not shown).
Data analysis. Data are expressed as mean  SEM.
Comparison of O2
 production between nonfailing and
failing tissue was performed by Student unpaired t test.
Comparisons within groups were performed by one-way
analysis of variance followed by Dunnett’s test. A p value 
0.05 was considered statistically significant.
RESULTS
NADPH oxidase activity in nonfailing and failing
myocardium. NADPH-dependent O2
 production was
readily detectable in both nonfailing and failing myocar-
dium. However, oxidase activity was significantly higher in
end-stage failing compared with nonfailing myocardium
(5.86  0.41 vs. 3.72  0.39 arbitrary units, respectively; p
 0.01) (Fig. 1A).
NADPH-dependent chemiluminescence was virtually
abolished by the O2
 scavenger Tiron in both groups,
confirming O2
 as the measured species. Myocardial O2

production was abolished by the flavoprotein inhibitor DPI
in both groups but was unaltered by a nitric oxide synthase
inhibitor (L-NAME), an inhibitor of mitochondrial ROS
production (rotenone), or a xanthine oxidase inhibitor
(oxypurinol), supporting a phagocyte-type NADPH oxidase
as the likely source (Fig. 1B).
NADPH oxidase expression and localization within the
myocardium. All four major oxidase subunits were detect-
able at both mRNA (not shown) and protein level in
end-stage failing as well as nonfailing human heart (Fig.
1C). However, there were no significant differences in
protein expression level of oxidase subunits between the two
groups (Fig. 1D). Likewise, the mRNA expression level of
each subunit was similar in the two groups (data not
shown).
To examine the cellular localization of NADPH oxidase
subunits, immunohistochemical studies were undertaken on
sections of nonfailing and failing myocardium (n  3 hearts
each; Figs. 2 and 3). These experiments were focused on
gp91phox, the subunit responsible for catalytic activity of the
oxidase, and p47phox, which is thought to play a key
regulatory role in oxidase activation following its transloca-
tion to the cell membrane, where it associates with gp91phox
and p22phox (14). In nonfailing hearts, there was a low
amount of positive staining for gp91phox in cardiac myocytes
(Figs. 2A and 2C) as well as the endothelium of cardiac
vessels (data not shown). In failing hearts, gp91phox immu-
noreactivity was particularly prominent on sarcolemmal
membranes and also intracellularly (Figs. 2B and 2D).
Co-staining for alpha-actinin as a myocyte marker, which
typically labels intracellular costamers and intercalated discs,
confirmed that gp91phox was expressed in cardiomyocytes
(Figs. 2E to 2H).
Positive staining for p47phox was also detected both in
nonfailing and failing heart tissue. Figure 3A shows exam-
ples of nonfailing and failing heart sections co-stained for
p47phox and alpha-actinin, and confirms that p47phox was
expressed in cardiomyocytes. Interestingly, p47phox immu-
noreactivity appeared to be significantly increased in the
cardiomyocyte sarcolemma of failing hearts (Fig. 3A, panels
d and f vs. a and c), suggesting a translocation of p47phox
Table 1. Information Regarding Oligonucleotide Primers Used in Study
Primer
Target
PCR Product Size,
Base Pairs
Number
of Cycles Primer Sequence (5 - 3)
gp91phox 528 28 forward-ATGGTGGCGTGGATGATTGCA
reverse-GAACATGGGACCCACGATCCA
p22phox 316 26 forward-GTTTGTGTGCCTGCTGGAGT
reverse-TGGGCGGCTGCTTGATGGT
p47phox 767 32 forward-ACCCAGCCAGCACTATGTGT
reverse-AGTAGCCTGTGACGTCGTCT
p67phox 746 28 forward-CGAGGGAACCAGCTGATAGA
reverse-CATGGGAACACTGAGCTTCA
cTnI 125 20 forward-TCCTCCAACTACCGCGCTTA
reverse-CTCGCTCCAGCTCTTGCTTT
cTnI  cardiac troponin I; PCR  polymerase chain reaction.
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Figure 1. Myocardial nicotinamide adenine dinucleotide 3-phosphate (reduced form) (NADPH) oxidase expression and activity in nonfailing and end-stage failing human heart. (A) NADPH-dependent
superoxide production in left ventricular homogenates measured by lucigenin-enhanced chemiluminescence. *p  0.01 between groups. (B) Effect of specific inhibitors (Inhib) of enzymatic reactive oxygen
species (ROS) production or of the superoxide scavenger Tiron. ††p  0.001 for ROS production with and without inhibitor. (C) Representative immunoblots for NADPH oxidase subunits and for cardiac
troponin I (cTnI). (D) Densitometric quantification of NADPH oxidase subunit expression relative to troponin I. DCM  dilated cardiomyopathy; DPI  diphenyleneiodonium; NYHA  New York Heart
Association; L-NAME  N-nitro-L-arginine methyl ester.
2167
JACC
Vol.41,No.12,2003
Heym
es
et
al.
June
18,2003:2164–71
NADPH
Oxidase
in
Hum
an
Heart
Failure
from the cytosol to membrane in end-stage CHF. This was
corroborated in sections co-stained for p47phox and vinculin
as a sarcolemmal marker (Fig. 3B), which demonstrated a
distinctly sarcolemmal pattern of p47phox labeling in failing
human heart.
DISCUSSION
This study provides the first evidence that a phagocyte-type
NADPH oxidase is expressed in human myocardium and
specifically in cardiomyocytes. We also show that NADPH
Figure 2. Representative immunofluorescence micrographs of human heart sections labeled for the nicotinamide adenine dinucleotide 3-phosphate (reduced
form) oxidase subunit gp91phox. Panels a, c, e, and g show nonfailing heart tissue and panels b, d, f, and h show end-stage failing tissue. Transverse (a,
b) and longitudinal (c, d) sections labeled for gp91phox show increased labeling in end-stage heart failure. Labeling for alpha-actinin (e, f) shows a typical
intracellular pattern of myocyte costamer and intercalated disc labeling. Panels g and h show suprerposition of gp91phox and alpha-actinin labeling. All scale
bars  20 m.
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oxidase activity is increased in the end-stage failing human
heart and that it is likely to be an important source of
increased cardiac ROS in human CHF.
Numerous studies indicate an important role for
NADPH oxidases in vascular pathologies such as hyperten-
sion (15) and atherosclerosis (17). Of relevance to heart
failure and potential myocardial ROS production, NADPH
oxidase are activated by angiotensin II, noradrenaline, tu-
mor necrosis factor-alpha, and increased mechanical forces
(13,14)—all of which may be implicated in CHF patho-
Figure 3. Representative immunofluorescence micrographs of human heart sections labeled for the nicotinamide adenine dinucleotide 3-phosphate (reduced
form) oxidase subunit p47phox. (A) Dual labeling for p47phox and alpha-actinin in nonfailing (a– c) and end-stage failing tissue (b–f). Panels a and d show
labeling for p47phox; panels b and e show labeling for alpha-actinin; panels c and f show superimposed images. p47phox was detected in cardiac myocytes
in both failing and nonfailing myocardium, with increased sarcolemmal labeling in the failing group (d and f vs. a and c). All scale bars  20 m. (B)
Dual labeling for p47phox and vinculin, as a sarcolemmal marker, in nonfailing (a– c) and end-stage failing tissue (b–f). Panels a and d show labeling for
p47phox; panels b and e show labeling for vinculin. Superposition of the p47phox and vinculin images (panels c and f) demonstrates the sarcolemmal
localization of p47phox in the end-stage heart tissue (panel f, yellow color). All scale bars  20 m.
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physiology. Indeed, recent studies in isolated cardiomyo-
cytes and in-vivo animal models have implicated NADPH
oxidase-derived ROS production in myocardial pathology
(19–22,25). In the present study, NADPH oxidase rather
than dysfunctional nitric oxide synthase, xanthine oxidase,
or mitochondrial production was the source of NADPH-
dependent ROS production because the latter was inhibited
by DPI but not by L-NAME, oxypurinol, or rotenone. The
evidence of oxidase subunit gene and protein expression in
cardiac myocytes strengthened this conclusion, with no
evidence of significant myocardial inflammatory infiltration.
The extent of increase in NADPH oxidase activity observed
in this study was comparable to that which was associated
with significant biological effects in previous cardiovascular
studies (15–17,20,21). Taken together, the present findings
and data from recent experimental reports (19–22,25)
suggest that NADPH oxidase-derived myocardial ROS
may play a significant role in the pathophysiology of human
CHF.
The NADPH oxidase complex comprises a membrane-
bound cytochrome b558 (consisting of one p22
phox and one
gp91phox subunit) and four cytosolic subunits (p47phox,
p67phox, p40phox and rac1), which translocate and associate
with the cytochrome during acute oxidase activation (14).
Chronic NADPH oxidase activation occurs through: 1)
post-translational protein modifications and translocation of
regulatory subunits (notably p47phox), or 2) an increase in
oxidase subunit expression (13,14). Interestingly, in the
present study the increase in NADPH oxidase activity in
end-stage failing heart appeared to be due to p47phox
translocation to the cardiomyocyte sarcolemma rather than
significant increases in oxidase subunit expression.
Increased oxidative stress may have several effects in the
diseased heart. Activation of redox-sensitive signaling path-
ways leads to altered gene expression and has been impli-
cated in the development of cardiac hypertrophy, fibrosis,
and remodeling (7,9,19,21,22,25), as well as adaptive alter-
ations such as an increase in catalase expression (26).
Increased oxidative stress promotes myocyte apoptosis (7)
and causes vascular endothelial dysfunction due to reduced
nitric oxide bioavailability (5). Key proteins involved in
myocardial excitation-contraction coupling, such as sar-
colemmal ion channels, sarcoplasmic reticulum calcium
release channels, and myofilament proteins, can also un-
dergo redox-sensitive alterations in activity (27–29). Re-
cently, it was suggested that ROS can modulate the inotro-
pic response to beta-adrenergic stimulation (30).
A limitation of the present study is the source of “control”
tissue used. The neurohumoral and hemodynamic status of
“donor” subjects before organ retrieval is unlikely to be
completely “normal,” whereas true healthy control human
tissue can rarely be ethically obtained for obvious reasons.
However, there are no data to suggest that neurohumoral or
cytokine activation downregulates oxidase activity; in fact,
oxidase activity may be upregulated in the donors by these
factors (13,22), which would have the effect of artifactually
reducing the true difference between the two groups.
In summary, this study provides the first data implicating
an increase in myocardial NADPH oxidase expression and
activity in the pathophysiology of human CHF.
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